Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Curr Hypertens Rep. 2012 Apr;14(2):111-9. doi: 10.1007/s11906-012-0248-9.
Over the past decade, vitamin D has generated considerable interest as potentially having important effects on the vasculature and the kidney. Animal and human data indicate that vitamin D suppresses the activity of the renin-angiotensin system and improves endothelial function. Observational studies in humans suggest that low 25-hydroxyvitamin D (25[OH]D) levels are associated with a higher risk of hypertension. However, findings from randomized trials of vitamin D supplementation (with cholecalciferol or ergocalciferol) to lower blood pressure are inconsistent, possibly stemming from variability in study population, sample size, vitamin D dose, and duration. Supplementation with activated vitamin D (i.e., 1,25-dihydroxyvitamin D or analogues) in patients with chronic kidney disease reduces urine albumin excretion, an important biomarker for future decline in renal function. These studies are reviewed, with special emphasis on recent findings. Definitive studies are warranted to elucidate the effects of vitamin D supplementation on mechanisms of hypertension and kidney disease.
在过去的十年中,维生素 D 因其对血管和肾脏可能具有重要影响而引起了相当大的关注。动物和人类数据表明,维生素 D 抑制肾素-血管紧张素系统的活性并改善内皮功能。人体观察性研究表明,低 25-羟维生素 D(25[OH]D)水平与高血压风险增加相关。然而,用胆钙化醇或麦角钙化醇补充维生素 D 以降低血压的随机试验结果不一致,这可能源于研究人群、样本量、维生素 D 剂量和持续时间的差异。在慢性肾脏病患者中补充活性维生素 D(即 1,25-二羟维生素 D 或类似物)可降低尿白蛋白排泄,这是肾功能未来下降的一个重要生物标志物。对这些研究进行了综述,特别强调了最近的发现。有必要进行明确的研究,以阐明维生素 D 补充对高血压和肾脏病发病机制的影响。